U.S. Prostate Cancer Nuclear Medicine Diagnostics Market Share To Reach Scalable Heights Of Growth
U.S. Prostate Cancer Nuclear Medicine Diagnostics Market Summary The U.S. prostate cancer nuclear medicine diagnostics market size was valued at USD 75.06 million in 2022 and is projected to expand at a compound annual growth rate (CAGR) of 9.2% from 2023 to 2030. The increasing incidence of prostate cancer continues to be one of the major factors driving the demand for early and accurate diagnostic solutions. According to the American Society of Clinical Oncology (ASCO), prostate cancer ranks as the second most common cancer among men, following skin cancer. In 2023 alone, an estimated 288,300 men in the United States are expected to receive a prostate cancer diagnosis. On a global level, approximately 1,414,259 individuals were diagnosed with prostate cancer in 2020, making it the fourth most frequently diagnosed type of cancer worldwide. Around 60% of these cases occur in individuals aged 65 years or older, with the average age of diagnosis at 66. The disease remai...